Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Alpha-1 Antitrypsin for COVID-19
NCT04385836Phase 1Unknown
- Sponsor
- Ministry of Health
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in coronavirus disease 2019 (COVID-19) comparing alpha one antitrypsin group with placebo group (2 arms). Primary endpoint: Clinical improvement at 3 weeks. Status: unknown.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04385836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385836.